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60 Poster Session Iregimens. With a median follow-up of 15 months from relapse (0.5–
52), 12 pts are alive, 9 in remission. The most important predicting
factor for survival after relapse was the duration of remission. Pts re-
lapsing . 6 months and\ 6 months after SCT had a median sur-
vival of 7.2 and 1.4 months and estimated 2-year survival of 22%
and 2%, respectively (p \ 0.001). Survival rates were 20%, 0%
and 4% after BuCy, FB2 and FB4, respectively (p 5 0.04). SCT
in refractory disease was also predictive of poor outcome after re-
lapse (p\0.001). Multivariable analysis determined short remission
after SCT and conditioning with FB regimens as independent ad-
verse factors with hazard ratios of 3.3 (1.9–6.3, p\ 0.001) and 2.0
(1.0–4.0, p 5 0.04), respectively. In conclusion the notion that pts
given RIC can be salvaged more easily if they relapse is not substan-
tiated and should not be a rationale to select RIC over myeloablative
conditioning.159
FEASIBILITY OF CLOFARABINE CYTOREDUCTION BEFORE INITIATION
OF ALLOGENEIC STEM CELL TRANSPLANT REGIMEN DURING THE CY-
TOPENIC PHASE FOR PATIENTS WITH REFRACTORY ACUTE MYELOGE-
NOUS LEUKEMIA
Locke, F.L., Artz, A.S., Rich, E.S., van Besien, K., Stock, W. The Uni-
versity of Chicago, Chicago, IL.
Patients with refractory leukemia entering allogeneic stem cell
transplant (Allo-SCT) fare poorly, and higher disease burden corre-
lates with decreased disease free survival (DFS) (van Besien, JCO
2005). To determine the feasibility of clofarabine (CLO) cytoreduc-
tive therapy as a bridge to Allo-SCT we retrospectively analyzed 14
heavily pretreated refractory acute myelogenous leukemia (AML)
pts. All pts received CLO 30–40 mg/m2 intravenous daily for five
consecutive days as bridging therapy with the intention to initiate
Allo-SCT conditioning during the cytopenic phase, 14–21 days
later. Pts had a mean of 2.2 prior treatment regimens, and 8 had pri-
mary refractory leukemia. 4 pts were relapsed following a prior stem
cell transplant (1 autologous and 3 Allo-SCT).
To assess CLO cytoreduction, bone marrow (BM) biopsy and as-
pirate were performed at the nadir, day 12 after CLO. Cytoreduc-
tion was defined as post CLO marrow with\20% cellularity and
\10% blasts. CLO achieved cytoreduction in 8/14 pts. The median
BM cellularity was 45% (4–90%) before and 5% (1–83%) after
CLO. The median BM blast % was 23% (10%-100%) before and
6% (0%-90%) after CLO.
Of the 14 pts, 13 proceeded to Allo-SCT by day 26 (median 22,
range 17–26). 7 pts received a fludarabine, busulfan, campath regi-
men; 5 pts received fludarabine, melphalan with either ATG (2) or
Campath (3); 1 pt received a TBI-based regimen. Grade 4 hyperbi-
lirubinemia prevented one pt from proceeding to Allo-SCT prepar-
ative regimen.
Of the 13 pts receiving Allo-SCT the median follow up is 15
months for survivors. 3 pts are alive and disease free at 4.3, 16.5,
and 40 months after Allo-SCT, and all achieved CLO cytoreduc-
tion. 2 pts are alive with progressive disease at 8 and 15 months.
The overall DFS at day 100 was 9/13. 3 pts relapsed before day
100, 2 of whom did not achieve cytoreduction. Beyond day 100
an additional 3 pts relapsed at 5.5, 5.5, and 6.5 months. 1 pt died
of treatment related motality (TRM), sepsis, at day 17. The TRM
at day 100 was 1/13, and 4/13 at one year.
In conclusion, 13/14 patients with refractory AML were able to
undergo Allo-SCT with acceptable TRM in this heavily pretreated
group after CLO re-induction. Based on these data, we are pursuing
a prospective feasibility study of CLO cytoreduction followed by
Allo-SCT during the cytopenic phase.160
PLASMA AND CSF PHAMACOKINETICS (PK) AND RESPONSE TO DASATI-
NIB IN A YOUNG CHILDWITH RELAPSING Ph1 ALL AFTER ALLOGENEIC
TRANSPLANT
Morris, C.L.1, Brown, W.C.2, Zappia, J.3, Morris, J.1 1Loma Linda
University Medical Center, Loma Linda, CA; 2Loma Linda University
Medical Center, Loma Linda, CA; 3Loma Linda University Medical
Center, Loma Linda, CA.Background: Dasatinib is a second-generation abl tyrosine ki-
nase inhibitor approved for patients with imatinib-intolerant or re-
sistant CML and Ph1 ALL. Plasma PK has not been studied in
children or CSF.Methods: Prospective analysis of dasatinib plasma
and CSF levels and clinical response in an 8-year-old male with Ph1
ALL in relapse (diagnosed at age 6 y). Serum and CSF levels were
determined by liquid chromatography tandem mass spectrometry
with a detection limit of 1 ng/ml. Results: The patient received
an unrelated donor stem cell transplant in 1st remission and a second
transplant following relapse 6 mo later. He received Imatinib 300
mg po QD (15 mg/kg) during consolidation, maintenance, and fol-
lowing his 1st transplant. He developed headache, leg pain, and a sin-
gle skin nodule of leukemia 7 mo after his last transplant. CSF had 7
blasts/ul, head CT showed hyper-intense chloromas in frontal, pa-
rietal, and temporal lobes, and a right ileopsoas mass. Bone marrow
was in remission, peripheral blood had 0.15% BCR/ABL by RT-
PCR. Dasatinib 40 mg po bid (1.5 mg/kg) was started. No other
chemotherapy was given. Clinical symptoms resolved after 6 days.
After 9 the CNS lesions became hypointense. Two large frontal
lobe masses, 1 parenchymal and 1 extra-axial, decreased in volume
from15 cc to 1.1 cc and CSF blasts to\1/ul. By day 23 the chlor-
omas had nearly resolved and CSF blasts were 0 by day 34. The
psoas mass resolved after 14 d. Plasma PK was measured 3 times,
and CSF 6 times at various points after dose. CNS response varied
with plasma level. Plasma levels after 7 d on 40 mg bid were slightly
lower than expected from adult data, (AUC 146 ng-h/ml, Cmax
40.4 ng-h/ml, and T1/2 2.2 hours). CSF levels were not detected
at any time point. On day 171 the patient developed disseminated
adenovirus and died on day 178. Post mortem showed no leukemia
in blood, marrow, or psoas muscle tissue by RT-PCR. There was
microscopic perivascular leukemia cell infiltration in the frontal
lobe, thalamus, and cerebellum. There was no evidence of CNS in-
fection. Conclusions: In this child plasma PK was similar to results
in adults. Ph1 leukemia in the CNS may respond to dasatinib de-
spite very low drug levels in the CSF.161
SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR ACUTE LEUKEMIAS RELAPSING AFTER FIRST TRANSPLANT IN PE-
DIATRIC PATIENTS
Martinez, C., Verneris, M.R., Weigel, B.J., Kumar, A., Baker, K.S.
University of Minnesota, Minneapolis, MN.
Recurrent leukemia is the most frequent indication for second al-
logeneic hematopoietic cell transplantation (HCT) in pediatric pa-
tients. However, there are few reports describing in detail the
overall survival in children who undergo a second stem cell trans-
plant procedure. We present our experience from the University
of Minnesota describing the outcome of 23 patients with either
acute lymphoblastic leukemia (ALL, n5 9) or acute myeloid leuke-
mia/myelodysplastic syndrome (AML/MDS, n 5 14) who had re-
lapsed after a first HCT and received a second allogeneic
transplant. The median age at the time of second transplant was
10 yrs for the AML/MDS patients and 6.8 yrs for the ALL patients.
All of the ALL patients were in complete remission at time of sec-
ond transplant, for the AML/MDS patients 6 were in remission
and 8 had active leukemia at the time of second HCT. The mean
time from first transplant to relapse for the ALL group was 406
days (range 0–729) and 619 days (range 20–4410) for the AML/
MDS group. Five patients received a second HCT from the same
donor source, 6 patients who had prior autologous HCT received
an unrelated donor (n5 5) or related donor (n5 1) for their second
HCT, and the remaining patients (n5 12) received a different allo-
geneic stem cell source. All of the patients except one patient with
AML/MDS received myeloablative conditioning with the second
HCT. Patients who received TBI with the first HCT were treated
with chemotherapy only conditioning regimens and those who had
not received TBI with the first HCT were treated with TBI based
regimens for the second HCT. The mean follow-up of the patients
with AML/MDS was 543 days (range 72–2109) and 708 days (range
23–2064) for the ALL group. The overall survival was 30% (n5 7),
four of fourteen survived in the AML/MDS group and three of nine
in the ALL group. Among the survivors the mean time from first
